866-997-4948(US-Canada Toll Free)

Parkinsons Disease - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 879 Pages

Parkinson's Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Parkinson's Disease Pipeline Review, H2 2016, provides an overview of the Parkinson's Disease (Central Nervous System) pipeline landscape.

Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinsons disease. Parkinsons disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Parkinson's Disease Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Parkinson's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 30, 37, 5, 173, 42 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 50, 15 and 1 molecules, respectively.

Parkinson's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Parkinson's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Parkinson's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Parkinson's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Parkinson's Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Parkinson's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Parkinson's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 10
Parkinson's Disease Overview 11
Therapeutics Development 12
Parkinson's Disease - Therapeutics under Development by Companies 14
Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes 30
Parkinson's Disease - Pipeline Products Glance 33
Parkinson's Disease - Products under Development by Companies 37
Parkinson's Disease - Products under Investigation by Universities/Institutes 56
Parkinson's Disease - Companies Involved in Therapeutics Development 60
Parkinson's Disease - Therapeutics Assessment 245
Drug Profiles 274
Parkinson's Disease - Dormant Projects 797
Parkinson's Disease - Discontinued Products 822
Parkinson's Disease - Product Development Milestones 825
Appendix 839

List of Tables
Number of Products under Development for Parkinson's Disease, H2 2016 51
Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2016 52
Number of Products under Development by Companies, H2 2016 53
Number of Products under Development by Companies, H2 2016 (Contd..1) 54
Number of Products under Development by Companies, H2 2016 (Contd..2) 55
Number of Products under Development by Companies, H2 2016 (Contd..3) 56
Number of Products under Development by Companies, H2 2016 (Contd..4) 57
Number of Products under Development by Companies, H2 2016 (Contd..5) 58
Number of Products under Development by Companies, H2 2016 (Contd..6) 59
Number of Products under Development by Companies, H2 2016 (Contd..7) 60
Number of Products under Development by Companies, H2 2016 (Contd..8) 61
Number of Products under Development by Companies, H2 2016 (Contd..9) 62
Number of Products under Development by Companies, H2 2016 (Contd..10) 63
Number of Products under Development by Companies, H2 2016 (Contd..11) 64
Number of Products under Development by Companies, H2 2016 (Contd..12) 65
Number of Products under Development by Companies, H2 2016 (Contd..13) 66
Number of Products under Development by Companies, H2 2016 (Contd..14) 67
Number of Products under Development by Companies, H2 2016 (Contd..15) 68
Number of Products under Investigation by Universities/Institutes, H2 2016 69
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 70
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 71
Comparative Analysis by Late Stage Development, H2 2016 72
Comparative Analysis by Clinical Stage Development, H2 2016 73
Comparative Analysis by Early Stage Development, H2 2016 74
Comparative Analysis by Unknown Stage Development, H2 2016 75
Products under Development by Companies, H2 2016 76
Products under Development by Companies, H2 2016 (Contd..1) 77
Products under Development by Companies, H2 2016 (Contd..2) 78
Products under Development by Companies, H2 2016 (Contd..3) 79
Products under Development by Companies, H2 2016 (Contd..4) 80
Products under Development by Companies, H2 2016 (Contd..5) 81
Products under Development by Companies, H2 2016 (Contd..6) 82
Products under Development by Companies, H2 2016 (Contd..7) 83
Products under Development by Companies, H2 2016 (Contd..8) 84
Products under Development by Companies, H2 2016 (Contd..9) 85
Products under Development by Companies, H2 2016 (Contd..10) 86
Products under Development by Companies, H2 2016 (Contd..11) 87
Products under Development by Companies, H2 2016 (Contd..12) 88
Products under Development by Companies, H2 2016 (Contd..13) 89
Products under Development by Companies, H2 2016 (Contd..14) 90
Products under Development by Companies, H2 2016 (Contd..15) 91
Products under Development by Companies, H2 2016 (Contd..16) 92
Products under Development by Companies, H2 2016 (Contd..17) 93
Products under Development by Companies, H2 2016 (Contd..18) 94
Products under Investigation by Universities/Institutes, H2 2016 95
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 96
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 97
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 98
Parkinson's Disease - Pipeline by 2-BBB Medicines BV, H2 2016 99
Parkinson's Disease - Pipeline by 4P Therapeutics LLC, H2 2016 100
Parkinson's Disease - Pipeline by AbbVie Inc, H2 2016 101
Parkinson's Disease - Pipeline by AC Immune SA, H2 2016 102
Parkinson's Disease - Pipeline by Acelot Inc, H2 2016 103
Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H2 2016 104
Parkinson's Disease - Pipeline by Adamas Pharmaceuticals Inc, H2 2016 105
Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 106
Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd, H2 2016 107
Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 108
Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2016 109
Parkinson's Disease - Pipeline by Amabiotics SAS, H2 2016 110
Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2016 111
Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H2 2016 112
Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H2 2016 113
Parkinson's Disease - Pipeline by Angita BV, H2 2016 114
Parkinson's Disease - Pipeline by Antoxis Ltd, H2 2016 115
Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2016 116
Parkinson's Disease - Pipeline by APeT Holding BV, H2 2016 117
Parkinson's Disease - Pipeline by ApoPharma Inc, H2 2016 118
Parkinson's Disease - Pipeline by Aposense Ltd, H2 2016 119
Parkinson's Disease - Pipeline by Araclon Biotech SL, H2 2016 120
Parkinson's Disease - Pipeline by ArmaGen Inc, H2 2016 121
Parkinson's Disease - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 122
Parkinson's Disease - Pipeline by AstraZeneca Plc, H2 2016 123
Parkinson's Disease - Pipeline by AudioCure Pharma GmbH, H2 2016 124
Parkinson's Disease - Pipeline by Berg LLC, H2 2016 125
Parkinson's Disease - Pipeline by Bial - Portela & Ca SA, H2 2016 126
Parkinson's Disease - Pipeline by Bio-Modeling Systems SAS, H2 2016 127
Parkinson's Disease - Pipeline by BioArtic AB, H2 2016 128
Parkinson's Disease - Pipeline by Biogen Inc, H2 2016 129
Parkinson's Disease - Pipeline by BioHealthonomics Inc, H2 2016 130
Parkinson's Disease - Pipeline by Biopharm GmbH, H2 2016 131
Parkinson's Disease - Pipeline by Biotie Therapies Corp, H2 2016 132
Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 133
Parkinson's Disease - Pipeline by Calico LLC, H2 2016 134
Parkinson's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H2 2016 135
Parkinson's Disease - Pipeline by Cardax Inc, H2 2016 136
Parkinson's Disease - Pipeline by Carna Biosciences Inc, H2 2016 137
Parkinson's Disease - Pipeline by Cell Cure Neurosciences Ltd, H2 2016 138
Parkinson's Disease - Pipeline by Cellceutix Corp, H2 2016 139
Parkinson's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2016 140
Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H2 2016 141
Parkinson's Disease - Pipeline by Clera Inc, H2 2016 142
Parkinson's Disease - Pipeline by Clevexel Pharma SA, H2 2016 143
Parkinson's Disease - Pipeline by Contera Pharma ApS, H2 2016 144
Parkinson's Disease - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016 145
Parkinson's Disease - Pipeline by Corium International Inc, H2 2016 146
Parkinson's Disease - Pipeline by Curemark LLC, H2 2016 147
Parkinson's Disease - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 148
Parkinson's Disease - Pipeline by Denali Therapeutics Inc, H2 2016 149
Parkinson's Disease - Pipeline by Depomed Inc, H2 2016 150
Parkinson's Disease - Pipeline by DermaXon LLC, H2 2016 151
Parkinson's Disease - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 152
Parkinson's Disease - Pipeline by Dizlin Medical Design AB, H2 2016 153
Parkinson's Disease - Pipeline by Domain Therapeutics SA, H2 2016 154
Parkinson's Disease - Pipeline by Edison Pharmaceuticals Inc, H2 2016 155
Parkinson's Disease - Pipeline by Eli Lilly and Company, H2 2016 156
Parkinson's Disease - Pipeline by Ensemble Therapeutics Corp, H2 2016 157
Parkinson's Disease - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2016 158
Parkinson's Disease - Pipeline by FPRT Bio Inc, H2 2016 159
Parkinson's Disease - Pipeline by Genecode AS, H2 2016 160
Parkinson's Disease - Pipeline by Generon (Shanghai) Corp Ltd, H2 2016 161
Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 162
Parkinson's Disease - Pipeline by GenKyoTex SA, H2 2016 163
Parkinson's Disease - Pipeline by Genmab A/S, H2 2016 164
Parkinson's Disease - Pipeline by Genosco Inc, H2 2016 165
Parkinson's Disease - Pipeline by Genzyme Corp, H2 2016 166
Parkinson's Disease - Pipeline by H. Lundbeck A/S, H2 2016 167
Parkinson's Disease - Pipeline by Harbor Therapeutics Inc, H2 2016 168
Parkinson's Disease - Pipeline by Heptares Therapeutics Ltd, H2 2016 169
Parkinson's Disease - Pipeline by Herantis Pharma Plc, H2 2016 170
Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2016 171
Parkinson's Disease - Pipeline by Horizon Pharma Plc, H2 2016 172
Parkinson's Disease - Pipeline by Huons Co Ltd, H2 2016 173
Parkinson's Disease - Pipeline by ICB International Inc, H2 2016 174
Parkinson's Disease - Pipeline by Immungenetics AG, H2 2016 175
Parkinson's Disease - Pipeline by Impel NeuroPharma Inc, H2 2016 176
Parkinson's Disease - Pipeline by Intec Pharma ltd, H2 2016 177
Parkinson's Disease - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 178
Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H2 2016 179
Parkinson's Disease - Pipeline by International Stem Cell Corp, H2 2016 180
Parkinson's Disease - Pipeline by Io Therapeutics Inc, H2 2016 181
Parkinson's Disease - Pipeline by Iproteos SL, H2 2016 182
Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 183
Parkinson's Disease - Pipeline by Kainos Medicine Inc, H2 2016 184
Parkinson's Disease - Pipeline by Khondrion BV, H2 2016 185
Parkinson's Disease - Pipeline by KineMed Inc, H2 2016 186
Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 187
Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 188
Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H2 2016 189
Parkinson's Disease - Pipeline by Living Cell Technologies Ltd, H2 2016 190
Parkinson's Disease - Pipeline by Longevity Biotech Inc, H2 2016 191
Parkinson's Disease - Pipeline by Luye Pharma Group Ltd, H2 2016 192
Parkinson's Disease - Pipeline by Lysosomal Therapeutics Inc, H2 2016 193
Parkinson's Disease - Pipeline by M et P Pharma AG, H2 2016 194
Parkinson's Disease - Pipeline by M's Science Corp, H2 2016 195
Parkinson's Disease - Pipeline by M3 Biotechnology Inc, H2 2016 196
Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc, H2 2016 197
Parkinson's Disease - Pipeline by MedImmune LLC, H2 2016 198
Parkinson's Disease - Pipeline by MeiraGTx Ltd, H2 2016 199
Parkinson's Disease - Pipeline by Merck & Co Inc, H2 2016 200
Parkinson's Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2016 201
Parkinson's Disease - Pipeline by Minerva Neurosciences Inc, H2 2016 202
Parkinson's Disease - Pipeline by Mission Therapeutics Ltd, H2 2016 203
Parkinson's Disease - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 204
Parkinson's Disease - Pipeline by MitoDys Therapeutics Ltd, H2 2016 205
Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H2 2016 206
Parkinson's Disease - Pipeline by Netherlands Translational Research Center BV, H2 2016 207
Parkinson's Disease - Pipeline by Neuralstem Inc, H2 2016 208
Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2016 209
Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 210
Parkinson's Disease - Pipeline by NeuroDerm Ltd, H2 2016 211
Parkinson's Disease - Pipeline by NeuroNascent Inc, H2 2016 212
Parkinson's Disease - Pipeline by NeurOp Inc, H2 2016 213
Parkinson's Disease - Pipeline by Neuropore Therapies Inc, H2 2016 214
Parkinson's Disease - Pipeline by New World Laboratories Inc, H2 2016 215
Parkinson's Disease - Pipeline by Newron Pharmaceuticals SpA, H2 2016 216
Parkinson's Disease - Pipeline by nLife Therapeutics SL, H2 2016 217
Parkinson's Disease - Pipeline by NLS Pharma Group, H2 2016 218
Parkinson's Disease - Pipeline by Novartis AG, H2 2016 219
Parkinson's Disease - Pipeline by Novo Nordisk A/S, H2 2016 220
Parkinson's Disease - Pipeline by NsGene A/S, H2 2016 221
Parkinson's Disease - Pipeline by Omeros Corp, H2 2016 222
Parkinson's Disease - Pipeline by Oncodesign SA, H2 2016 223
Parkinson's Disease - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 224
Parkinson's Disease - Pipeline by OPKO Health Inc, H2 2016 225
Parkinson's Disease - Pipeline by Orion Oyj, H2 2016 226
Parkinson's Disease - Pipeline by Oryzon Genomics SA, H2 2016 227
Parkinson's Disease - Pipeline by Oxford BioMedica Plc, H2 2016 228
Parkinson's Disease - Pipeline by ParkCell AB, H2 2016 229
Parkinson's Disease - Pipeline by Peptron Inc, H2 2016 230
Parkinson's Disease - Pipeline by Pfizer Inc, H2 2016 231
Parkinson's Disease - Pipeline by Pharma Two B Ltd, H2 2016 232
Parkinson's Disease - Pipeline by PharmatrophiX Inc, H2 2016 233
Parkinson's Disease - Pipeline by Pharmaxis Ltd, H2 2016 234
Parkinson's Disease - Pipeline by Pharmicell Co Ltd, H2 2016 235
Parkinson's Disease - Pipeline by Pharnext SA, H2 2016 236
Parkinson's Disease - Pipeline by Phenomenome Discoveries Inc, H2 2016 237
Parkinson's Disease - Pipeline by Plex Pharmaceuticals Inc, H2 2016 238
Parkinson's Disease - Pipeline by Prana Biotechnology Ltd, H2 2016 239
Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H2 2016 240
Parkinson's Disease - Pipeline by Primary Peptides Inc, H2 2016 241
Parkinson's Disease - Pipeline by Proclara Biosciences Inc, H2 2016 242
Parkinson's Disease - Pipeline by Promentis Pharmaceuticals Inc, H2 2016 243
Parkinson's Disease - Pipeline by Promius Pharma LLC, H2 2016 244
Parkinson's Disease - Pipeline by Proteostasis Therapeutics Inc, H2 2016 245
Parkinson's Disease - Pipeline by Prothena Corp Plc, H2 2016 246
Parkinson's Disease - Pipeline by QR Pharma Inc, H2 2016 247
Parkinson's Disease - Pipeline by reMYND NV, H2 2016 248
Parkinson's Disease - Pipeline by Retrotope Inc, H2 2016 249
Parkinson's Disease - Pipeline by Sage Therapeutics Inc, H2 2016 250
Parkinson's Disease - Pipeline by Saje Pharma LLC, H2 2016 251
Parkinson's Disease - Pipeline by SanBio Inc, H2 2016 252
Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics Inc, H2 2016 253
Parkinson's Disease - Pipeline by Saniona AB, H2 2016 254
Parkinson's Disease - Pipeline by Sellas Inc, H2 2016 255
Parkinson's Disease - Pipeline by Serina Therapeutics Inc, H2 2016 256
Parkinson's Disease - Pipeline by Shire Plc, H2 2016 257
Parkinson's Disease - Pipeline by Sigma-Tau SpA, H2 2016 258
Parkinson's Disease - Pipeline by SignPath Pharma Inc, H2 2016 259
Parkinson's Disease - Pipeline by Signum Biosciences Inc, H2 2016 260
Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 261
Parkinson's Disease - Pipeline by STATegics Inc, H2 2016 262
Parkinson's Disease - Pipeline by Stelic Institute & Co Inc, H2 2016 263
Parkinson's Disease - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 264
Parkinson's Disease - Pipeline by Sunovion Pharmaceuticals Inc, H2 2016 265
Parkinson's Disease - Pipeline by Synthonics Inc, H2 2016 266
Parkinson's Disease - Pipeline by Takara Bio Inc, H2 2016 267
Parkinson's Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 268
Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd, H2 2016 269
Parkinson's Disease - Pipeline by TechnoPhage SA, H2 2016 270
Parkinson's Disease - Pipeline by Teikoku Pharma USA Inc, H2 2016 271
Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 272
Parkinson's Disease - Pipeline by Titan Pharmaceuticals Inc, H2 2016 273
Parkinson's Disease - Pipeline by Trevena Inc, H2 2016 274
Parkinson's Disease - Pipeline by TyrNovo Ltd, H2 2016 275
Parkinson's Disease - Pipeline by UniQure NV, H2 2016 276
Parkinson's Disease - Pipeline by Vanton Research Laboratory LLC, H2 2016 277
Parkinson's Disease - Pipeline by Varinel Inc, H2 2016 278
Parkinson's Disease - Pipeline by VistaGen Therapeutics Inc, H2 2016 279
Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 280
Parkinson's Disease - Pipeline by Voyager Therapeutics Inc, H2 2016 281
Parkinson's Disease - Pipeline by vTv Therapeutics Inc, H2 2016 282
Parkinson's Disease - Pipeline by Wellstat Therapeutics Corp, H2 2016 283
Assessment by Monotherapy Products, H2 2016 284
Assessment by Combination Products, H2 2016 285
Number of Products by Stage and Target, H2 2016 287
Number of Products by Stage and Mechanism of Action, H2 2016 298
Number of Products by Stage and Route of Administration, H2 2016 310
Number of Products by Stage and Molecule Type, H2 2016 312
Parkinson's Disease - Dormant Projects, H2 2016 836
Parkinson's Disease - Dormant Projects (Contd..1), H2 2016 837
Parkinson's Disease - Dormant Projects (Contd..2), H2 2016 838
Parkinson's Disease - Dormant Projects (Contd..3), H2 2016 839
Parkinson's Disease - Dormant Projects (Contd..4), H2 2016 840
Parkinson's Disease - Dormant Projects (Contd..5), H2 2016 841
Parkinson's Disease - Dormant Projects (Contd..6), H2 2016 842
Parkinson's Disease - Dormant Projects (Contd..7), H2 2016 843
Parkinson's Disease - Dormant Projects (Contd..8), H2 2016 844
Parkinson's Disease - Dormant Projects (Contd..9), H2 2016 845
Parkinson's Disease - Dormant Projects (Contd..10), H2 2016 846
Parkinson's Disease - Dormant Projects (Contd..11), H2 2016 847
Parkinson's Disease - Dormant Projects (Contd..12), H2 2016 848
Parkinson's Disease - Dormant Projects (Contd..13), H2 2016 849
Parkinson's Disease - Dormant Projects (Contd..14), H2 2016 850
Parkinson's Disease - Dormant Projects (Contd..15), H2 2016 851
Parkinson's Disease - Dormant Projects (Contd..16), H2 2016 852
Parkinson's Disease - Dormant Projects (Contd..17), H2 2016 853
Parkinson's Disease - Dormant Projects (Contd..18), H2 2016 854
Parkinson's Disease - Dormant Projects (Contd..19), H2 2016 855
Parkinson's Disease - Dormant Projects (Contd..20), H2 2016 856
Parkinson's Disease - Dormant Projects (Contd..21), H2 2016 857
Parkinson's Disease - Dormant Projects (Contd..22), H2 2016 858
Parkinson's Disease - Dormant Projects (Contd..23), H2 2016 859
Parkinson's Disease - Dormant Projects (Contd..24), H2 2016 860
Parkinson's Disease - Discontinued Products, H2 2016 861
Parkinson's Disease - Discontinued Products (Contd..1), H2 2016 862
Parkinson's Disease - Discontinued Products (Contd..2), H2 2016 863

List of Figures
Number of Products under Development for Parkinson's Disease, H2 2016 51
Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2016 52
Number of Products under Development by Companies, H2 2016 53
Number of Products under Investigation by Universities/Institutes, H2 2016 69
Comparative Analysis by Late Stage Development, H2 2016 72
Comparative Analysis by Clinical Stage Development, H2 2016 73
Comparative Analysis by Early Stage Products, H2 2016 74
Comparative Analysis by Unknown Stage Development, H2 2016 75
Assessment by Monotherapy Products, H2 2016 284
Assessment by Combination Products, H2 2016 285
Number of Products by Top 10 Targets, H2 2016 286
Number of Products by Stage and Top 10 Targets, H2 2016 286
Number of Products by Top 10 Mechanism of Actions, H2 2016 297
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 297
Number of Products by Top 10 Routes of Administration, H2 2016 309
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 309
Number of Products by Top 10 Molecule Types, H2 2016 311
Number of Products by Stage and Top 10 Molecule Types, H2 2016 311

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *